All In MedTech

Device Trial Radar · NCT02295891

Miradry Treatment for Focal Axillary Hyperhidrosis

Microwave Energy-induced Thermolysis of Axillary Apocrine Glands and Hair Follicles Will Result in Improvement of Secondary Psychopathology Related to Hyperhidrosis.

Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

31

Actual

Start

Nov 2014

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary hyperhidrosis is a pathological condition characterized by the idiopathic and excessive secretion of sweat beyond normal physiological demand and is localized at particular foci such as the face, axilla, palms of the hands, and soles of the feet. Patients seeking medical attention for hyperhidrosis often report disruptions to their professional and/or social lives due to sweating and subsequently experience many psychosocial difficulties, such as anxiety, social phobia, and depression. Therefore, a psychiatric explanation of causality is frequently offered for these patients during diagnosis. Excessive sweating is often mistakenly interpreted as a symptom of an anxiety disorder and can be cause for social embarrassment, exacerbating emotional stress and social avoidance. As currently constituted, the treatment of secondary psychosocial symptoms in primary hyperhidrosis is poorly understood and requires further investigation.

Conditions

  • Axillary Hyperhidrosis

Interventions

  • MiraDry ®Device

    Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Severity as Assessed by the Hyperhidrosis Disease Severity Scale (HDSS)Time frame: Baseline, 6 months, 1 Year
  2. Quality of Life as Assessed by the Dermatology Quality of Life IndexTime frame: Baseline, 6 months, 1 Year
  3. Social Phobia as Assessed by the Social Phobia Inventory (SPIN)Time frame: Baseline, 6 months, 1 Year

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.